InvestorsHub Logo
Followers 105
Posts 4897
Boards Moderated 0
Alias Born 10/06/2011

Re: jour_trader post# 357316

Sunday, 06/13/2021 6:24:39 PM

Sunday, June 13, 2021 6:24:39 PM

Post# of 406807
Here is the link...https://seekingalpha.com/filings/pdf/14931880

Look at Lannett’s Income Statements and commentary on CNS results

Really, the income statement? No income statement provides a product breakdown. C'mon, man! That is such BS.

Well, I read the entire document...all of it...

There is nothing that specifies, refers, infers, implies, or offers the means to conclude any specific CNS drug accounts for the bulk of the CNS revenues that make up 22% of LCI's Q3 revenues.

Here is the company's "discussion" about product breakdown p.11...
[quoteSegment Information
The Company operates in one reportable segment, generic pharmaceuticals. As such, the Company aggregates its financial information for all products. The table below identifies the Company’s net sales by medical indication for the three and nine months ended March 31, 2021 and 2020.
(In thousands)
Medical Indication
Analgesic
Anti-Psychosis
Cardiovascular
Central Nervous System Endocrinology
Gastrointestinal
Infectious Disease
Migraine Respiratory/Allergy/Cough/Cold Urinary
Other
Contract manufacturing revenue Total net sales
Customer, Supplier and Product Concentration
Three Months Ended March 31,
Nine Months Ended March 31, 2021 2020

Stop peddling nonsense and disinformation about Elite. Interested in relevant discussion? Try this...
P. 39…While there have been some efforts by some of our customers to increase their inventory levels for the Company’s products in the near term, the Company has not seen significant increases in demand. The Company does not anticipate any significant changes in demand for its products in the future, however, depending on the duration and severity of the outbreak, levels of demand may change.

P. 46…The decrease in net sales was driven by a decrease in the selling price of products of $64.8 million partially offset by increased volumes of $29.7 million. The decrease in the selling price of products was primarily driven by lower sales prices of Fluphenazine, which is included within the Anti-Psychosis medical indication, and Posaconazole, which is included in Infectious Disease medical indication, due to new competitors entering the market, as well as lower average selling price across the remaining medical indications.

See any mention of Elite's drugs? Nah, neither did I.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News